Novartis Poised To Face Off With AstraZeneca In PNH After Second Iptacopan Trial

 
• By Jessica Merrill

The Phase III APPOINT-PNH study, testing iptacopan in treatment-naïve PNH patients, met its primary endpoint, positioning the oral drug as a potential new competitor to Soliris and Ultomiris.

dart board
Novartis said the second of two PHase III studies in PNH met their primary endpoint • Source: Shutterstock

More from Clinical Trials

More from R&D